Two families with hereditary renal amyloidosis were found to have a novel mutation in the fibrinogen Aa chain gene. This form of amyloidosis is an autosomal dominant condition characterized by proteinuria, hypertension, and subsequent azotemia.
Introduction
Hereditary amyloidosis is a heterogeneous syndrome characterized as a late-onset autosomal dominant disorder with amyloid deposition in various tissues. It was originally classified by clinical presentation, but progress in biochemistry has made it possible to classify it by amyloid precursor protein ( 1 ) . Several kinds of hereditary amyloidosis are known to be caused by single amino acid substitutions in precursor proteins: familial amyloid polyneuropathy (transthyretin, apolipoprotein Al, and gelsolin), familial Alzheimer's disease (amyloid precursor protein), and hereditary cerebral hemorrhage with amyloidosis (aamyloid precursor protein and cystatin C) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Hereditary renal amyloidosis (HRA)' is a relatively rare subtype ofhereditary systemic amyloidosis, where the principal organ involvement is renal. Since Ostertag described HRA in 1932 (13) , several kindreds have been reported. Although it was the first reported hereditary amyloidosis, the protein responsible for its amyloid deposit in most cases has remained unknown. In a previous study, we found a partial amino acid sequence of fibrinogen Aa chain with an amino acid substitution in deposited amyloid in a patient with HRA and proposed a variant fibrinogen Aa chain as a possible cause of HRA ( 14) .
In this paper, we report about two unrelated kindreds with HRA who share a novel mutant fibrinogen Aa chain gene.
Cases
The family pedigrees are shown in Fig. 1 . Both families are of Irish descent with all members presently living in the United States. Ancestors of these two kindreds immigrated to the United States in the 18th to mid-19th century independently. Exclusive genealogic study revealed no evidence of linkage between these two kindreds.
Family D. The propositus (1II-11 ) is a 53-yr-old man who, at the age of 43 , was noted on a yearly physical examination to have proteinuria, which increased during the next 3 yr to the nephrotic range. Amyloidosis was diagnosed by renal biopsy. A liver biopsy at age 51 revealed amyloid in blood vessel walls only. He has not had any cardiac or neurological symptoms.
Propositus' father (11-2) died at age 69 of renal failure. An autopsy showed amyloid in the kidneys (Fig. 2) and spleen, but not in the liver or heart. Each kidney weighed 90 g and the spleen weighed 250 g. He had paedal edema, but no signs of neuropathy.
This propositus' uncle noted the onset of severe, generalized pruritus at age 59 yr and was found to have proteinuria, anemia, and hypertension. Renal dysfunction and pancytopenia gradually progressed and he died at age 61.
A cousin of the propositus (III-1 ) was first found during an annual examination at age 61 yr to have proteinuria. Renal biopsy showed amyloid deposition. Renal dysfunction rapidly progressed in a year, and he is now on hemodialysis.
A 54-year-old brother of the propositus (III-10) was noted to have proteinuria, but no biopsy has been performed yet.
Family R. A 62-yr-old woman (16, 17) . Oligonucleotide primers (Fib3 primer 5'-CTTCGACACTGCCTCAACTG-3' and Fib2 primer 5'-TCCTCTGTTGTAACTCGTGCT-3') were synthesized to amplify a part of exon 5 of fibrinogen Aa chain gene (nucleotides 4832-505 1 ), which codes the carboxyl-terminal region of Aa chain found in a previous study ( 18, 14) . PCR was performed using primers, GeneAmp PCR reagents, 60MgM dNTPs, and 30 nM 32P-labeled dCTP (final concentration). PCR conditions were 30 cycles of denaturing at 940C for 30 s, annealing at 620C for 30 s, and extension at 720C for 1 min. PCR products were diluted with 100 vol of buffer containing 50% formamide, 0.05% SDS, 0.02% xylene cyanol FF, 0.02% bromophenol blue, and 10 mM EDTA, heated at 950C for 5 min and loaded onto a 0.5X MDE gel (40 x 20 X 0.04 cm). The gel was electrophoresed at 4VC for 16 h at 8 W, dried, and exposed to Kodak X-Omat film.
Direct DNA sequence analysis. DNA was examined by the direct DNA sequence method described previously ( 19). 10 Mul of symmetric PCR product was electrophoresed through 4% Nusieve GTG agarose gel. The band of 220 bp was cut out and melted in 300 ofTris-EDTA buffer. Asymmetric PCR was performed in 100 reaction using 10 microconcentrator. 2 ml ofTris-EDTA buffer was added to the sample, and the sample was centrifuged at 5,000 g for 30 min. This was repeated three times. 7 Al ofthe retentate was used for dideoxynucleotide sequencing reaction by Sequenase Version 2.0.
RFLP analysis. DNA samples from 16 members in family D (5 affected and II individuals at risk) and 14 in family R (2 affected and 12 individuals at risk) were examined by the PCR-induced mutation restriction analysis. A Fib4 primer (5'-CAGATTCTGAGCCCCTAG-TC-3'), which was arranged to give a recognition site of MaeIII in the mutant gene PCR products, was synthesized and used for amplification with Fib3 primer in the same condition as described above. PCR-amplified DNA fragments were digested with restriction enzyme MaeIII at 550C overnight, electrophoresed through 4% Nusieve GTG agarose gel, stained with ethidium bromide, and photographed under ultraviolet light.
Plasmafibrinogen studies. Plasma fibrinogen values of two affected members and five unaffected variant fibrinogen carriers were examined functionally by fibrin formation and immunologically by radial immunodiffusion (20, 21 ) . Thrombin and reptilase clotting times were performed as described before (22) .
Purification ofplasmafibrinogen. 36 ml of plasma anticoagulated with trisodium citrate (fibrinogen value; 340 mg/dl) was obtained from a family member who had been predicted by DNA analysis to be heterozygous for variant fibrinogen. Plasma was diluted to 100 ml with water and passed through a lysine Sepharose 4B column and a gelatin Sepharose 4B column equilibrated with 0.1 M phosphate buffer (pH 7.4) (23, 24). Ammonium sulfate was then added to the plasma to a final concentration of 25% and incubated for 1 h at 4VC (25) . Precipitated fibrinogen was collected by centrifugation for 30 min at 8,000 g. This ammonium sulfate precipitation was repeated three times. The precipitated fibrinogen was dialyzed against water and lyophilized. 108 mg of fibrinogen was obtained. The isolated fibrinogen was found to be highly pure on the basis of sodium dodecylsulfate polyacrylamide gel electrophoresis.
Isolation of residue 518-584 cyanogen bromide fragment of Aa chain. Purified plasma fibrinogen (20 mg) was treated with 2 ml of75% formic acid containing 200 mg of cyanogen bromide for 2 h at room temperature (26) . The volume was reduced to 1 ml with a stream of nitrogen gas, and the digest fractionated on a Sephadex G-50 superfine column ( 1.6 x 86 cm) equilibrated and eluted with 0.25% trifluoroacetic acid in water. Eluant was monitored by absorbance at 235 nm. The peak eluting after the large void volume peak was pooled and concentrated to -0.75 ml on a speed vac (Savant Instruments, Inc., Hicksville, NY), and 0.25 ml of 88% formic acid was added. An aliquot of the sample was fractionated on a 0.46 x 25-cm Ultrasphere-ODS column (Beckman Instruments, Carlsbad, CA) equilibrated with 0.1% trifluoroacetic acid, 10% acetonitrile in water, and eluted with a 10-50% acetonitrile gradient over 40 min. Eluant was monitored by absorbance at 215 nm. Peaks were dried in a speed vac.
Peptide sequence determination. Isolated peptides were sequenced on a protein sequencer (model 473A; Applied Biosystems, Inc., Foster City, CA) using the manufacturer's standard cycles. Results SSCP analysis revealed an abnormally migrating band in all three affected individuals; two from family R, and one from family D (Fig. 3) .
Direct DNA sequencing of PCR products of these three patients showed both adenine and thymine at position 4909 of fibrinogen gene (Fig. 4) ( 18) . Thus, they were heterozygous with both a normal GAG (glutamic acid) and a variant GTG (valine) codon at amino acid position 526 of fibrinogen Aa chain (27) . The sequence data of these cases were compatible with those of the normal gene except for the transversion.
PCR-RFLP analysis showed that all 7 affected individuals, D II-1, and 13 of 22 individuals at risk had the MaeIII recognition site associated with the Val 526 mutation, and therefore, had a digestion band of 76 bp, while 9 other individuals at risk showed a normal band of 98 bp (Fig. 5) .
The plasma fibrinogen values measured by both functional and immunochemical assays were within the normal range. Thrombin and reptilase clotting times of plasmas from seven members of these kindreds carrying the mutant fibrinogen gene were also normal. To determine if both normal and variant Aa chains were present in plasma fibrinogen, fibrinogen isolated from the plasma of an asymptomatic individual who was positive for the gene mutation was digested with cyanogen bromide and fractionated over a Sephadex G-50 superfine column. The Aa chain residue 518-584 cyanogen bromide frag- ment eluted in the peak after the large void volume peak containing the large disulfide bridged fragment of fibrinogen. This 518-584 peak was further fractionated by reverse-phase HPLC. Two approximately equal sized peaks eluted at 18.5 and 19.5 min (Fig. 6 ). Sequence analysis ofthe first peak for 20 cycles yielded the normal sequence of residues 518-537 of Aa chain:
LGEFVSETESRGSESGIFTN. Analysis of the second peak yielded the same sequence except for valine instead of glutamic acid in cycle 9 corresponding to residue 526 in the Aa chain, the substitution predicted from DNA analysis. Thus, both normal and variant Aa chain were present. In addition, equal yields ofthe two residues were obtained on the sequencer when the unfractionated peak was applied suggesting that equal amounts of normal and variant fibrinogen Aa chains were present in the plasma.
Discussion
The fibrinogen molecule consists of two identical ensembles each containing an Aa-, Bf3-, and y-polypeptide chain. The Aa chain is characteristically the largest of the three chains with 610 amino acid residues and a molecular weight of 66,066. Several fibrinogen Aa (28) . All variants have an amino acid substitution in the 19 residues ofthe amino terminus with exceptions of Aa 461 AAA (Lys) to TAA (Stop) mutation and Cys 554 mutation (29, 30, 31) .
In a previous study, we isolated a fragment of fibrinogen Aa chain (amino acid residues 500-580) with an amino acid substitution (Fib Aa Leu 554) from renal amyloid deposits in an individual of Peruvian descent (14) . Although no tissue was available for the examination of amyloid protein in the kindreds described here, the close linkage between the disease and the fibrinogen mutation that has never been reported before in individuals without amyloidosis, strongly suggests the variant fibrinogen to be amyloid precursor protein. In addition, preliminary immunohistological studies using an antiserum raised against the carboxyl-terminal region of fibrinogen revealed positive staining of amyloid deposits in tissue sections of these kindreds. We do not know whether the normal counterpart of the Aa chain is or is not involved in the amyloid deposition in these kindreds. As only variant Aa chain fragments were found in amyloid deposits ofthe previously characterized Leu 554 patient, it is likely that the amyloid deposits are derived exclusively from variant Aa chain in these kindreds, even though both normal and variant protein were reported to exist in amyloid deposits of transthyretin related amyloidosis patients with a normal/variant chain ratio of 1:2 (32, 33) .
Several proteins (transthyretin, apolipoprotein Al, gelsolin, and serum amyloid A) are known to be precursor proteins for systemic amyloidosis (1). Though the mechanisms by which these proteins deposit in tissue as amyloid are still unknown, the subunit peptides share two features; they are all derived from plasma proteins and all have molecular size of 8-14 kD.
Important questions in understanding amyloidogenesis with this fibrinogen Aa chain variant include how the mutation alters structure of the protein and how it affects metabolism ofthe protein. While it is possible that the fibrinogen molecule that contains variant Aa chain degrades more rapidly than the normal molecule, we found that individuals with the variant protein had plasma fibrinogen values in the normal range, and that approximately half of the fibrinogen Aa chain was variant in the individual we examined. This suggests that the amino acid substitution does not interfere with formation of the fibrinogen molecule, and there is no great difference in degradation rate between normal and variant Aa chain. It is likely that the variant Aa chain is contained within the fibrinogen molecule and becomes the amyloid peptide in the process of molecular degradation. The lack of clinical history of bleeding disorders and normal values obtained by clotting studies indicate that the mutation does not significantly affect clotting function in these kindreds.
The most distinctive feature of amyloidosis in these kindreds is that affected individuals have nephropathy as the major manifestation without evidence of neuropathy. Though the mechanism by which amyloid proteins have organ specificity that leads to the variation in clinical features is unknown, the nonneuropathic, nephropathic syndrome seems to be the prominent feature for fibrinogen Aa chain amyloidosis. 10 kindreds, including 2 kindreds described here and the one we studied previously, have been reported to have nonneuropathic, nephropathic amyloidoses. The kindred first described by Ostertag 
